{'fraction_non_alphanumeric': 0.03219512195121951, 'fraction_numerical': 0.001951219512195122, 'mean_word_length': 4.829545454545454, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nuclear steroid receptors in endometrial cancers.

Estrogen receptor in the cytosol (ERc), in the nuclear KCl extract (ERne), and in the nuclear KCl unextractable fraction (ERnu) of endometrial cancers was detected in all 3 premenopausal cases. In all postmenopausal cases. ERc was detected, but neither ERne nor ERnu were detected in several cases. These results suggest that an ER-mediated mechanism is present in all endometrial cancers. 
 
 
 
In 3 premenopausal cases, progestin receptor (PR) and androgen receptor (AR) were detected in the cytosol, and in the nuclear fractions of one well- and one moderately-differentiated tumor. In some postmenopausal cases, PRne was found but not PRc. ARc levels in endometrial cancers were always low in both pre- and postmenopausal cases. These findings indicate the presence of some factor by which the pro-gesterone-PRc complex translocates to the nucleus of endometrial cancer cells in some postmenopausal cases, and that the nucleus may have progestin-specific binding sites.